New insider activity at Arcutis Biotherapeutics ( (ARQT) ) has taken place on October 6, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Larry Todd Edwards, the EVP Chief Commercial Officer of Arcutis Biotherapeutics, has sold 4,207 shares of the company’s stock, amounting to a total transaction value of $84,055.
Recent Updates on ARQT stock
Arcutis Biotherapeutics has seen positive developments recently, with the U.S. FDA approving their supplemental new drug application for ZORYVE cream 0.05% for treating mild to moderate atopic dermatitis in young children. Additionally, new data presented at the EADV Congress highlighted the efficacy of Zoryve foam 0.3% across various skin conditions and diverse patient demographics, which has contributed to a positive outlook for the company. These advancements have led analysts to raise their price targets for Arcutis Biotherapeutics, reflecting optimism about the company’s growth prospects driven by Zoryve’s success and strategic initiatives.
Spark’s Take on ARQT Stock
According to Spark, TipRanks’ AI Analyst, ARQT is a Neutral.
Arcutis Biotherapeutics’ strong revenue growth and positive earnings call sentiment are significant strengths, contributing to a promising outlook. However, profitability challenges and valuation concerns moderate the overall score. Technical indicators support a bullish trend, but caution is advised due to approaching overbought conditions.
To see Spark’s full report on ARQT stock, click here.
More about Arcutis Biotherapeutics
YTD Price Performance: 36.81%
Average Trading Volume: 1,768,712
Technical Sentiment Signal: Buy
Current Market Cap: $2.39B